Antiepileptics in the treatment of schizophrenia

Antiepileptic Drugs to Treat Psychiatric Disorders

Volumn , Issue , 2008, Pages 187-206

  Citrome, Leslie ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85076661232     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849382666-14     Document Type: Chapter

References (85)

1. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State office of Mental Health. Psychiatr Q 1998; 69(4):283-300.
2. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51(5): 634-638.
3. Citrome L, Jaffe A, Levine J. Datapoints - mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr Serv 2002; 53(10):1212.
4. Citrome L. Antipsychotic polypharmacy versus augmentation with anticonvulsants: the US Perspective. Paper presented at: XXIV CINP Congress, Paris, France, 2004, June 20-24. Int J Neuropsychopharmacol 2004, 7(suppl 1):S69 (abstr).
5. Wessels T, Grunler D, Bunk C, et al. Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004. Psychiatr Q 2007; 78(2):91-99.
6. Davids E, Bunk C, Specka M, et al. Psychotropic drug prescription in a psychiatric university hospital in Germany. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1109-1116.
7. Grohmann R, Engel RR, Geissler KH, et al. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004; 37(suppl 1):S27-S38.
8. Mallinger JB, Lamberti JS. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. J Ment Health Policy Econ 2007; 10(1):15-22.
9. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(3):756-760.
10. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007; 58(4):489-495.
11. Hakola HP, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics. Lancet 1982; 1(8285):1358.
12. Luchins DL. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 1984; 20(3):569-571.
13. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983; 44(9):326-331.
14. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987; 22(4):303-310.
15. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80(3):250-259.
16. Nachshoni T, Levin Y, Levy A, et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994; 35(1):22-26.
17. Simhandl C, Meszaros K, Denk E, et al. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Can J Psychiatry 1996; 41(5):317.
18. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19(4):310-315.
19. Ohlmeier MD, Jahn K, Wilhelm-Gossling C, et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology 2007; 55(2):81-88.
20. Leucht S, Kissling W, McGrath J, et al. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007; 3:CD001258.
21. Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996; 153(5):711-713.
22. Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006; 20(3):219-231.
23. Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007; 27(3):279-283.
24. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129:114-119.
25. Nagao T, Ohshimo T, Mitsunobu K, et al. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979; 14(3):509-523.
26. Wassef AA, Hafiz NG, Hampton D, et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001; 21(1):21-26.
27. Chong SA, Tan CH, Lee EL, et al. Augmentation of risperidone with valproic acid. J Clin Psychiatry 1998; 59(8):430.
28. Ko GN, Korpi ER, Freed WJ, et al. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients. Biol Psychiatry 1985; 20(2):209-215.
29. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia revisited. Br J Psychiatry 1987; 150:542-546.
30. Dose M, Hellweg R, Yassouridis A, et al. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998; 31(4):122-125.
31. Wassef AA, Dott SG, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000; 20(3):357-361.
32. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28(1):182-192.
33. Abbott Laboratories. ABT-711 M02-547 Clinical Study Report. Available at: http://www.clinicalstudyresults.org/documents/company-study_782_0.pdf. Accessed November 20, 2006.
34. Citrome L, Shope CB, Nolan KA, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007; 22(6):356-362.
35. Citrome L, Casey DE, Daniel DG, et al. Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multicenter study. Psychiatr Serv 2004; 55(3):290-294.
36. Sajatovic M, Coconcea N, Ignacio RV, et al. Adjunct extended-release valproate semisodium in late life schizophrenia. Int J Geriatr Psychiatry 2008; 23(2):142-147.
37. Kelly DL, Conley RR, Feldman S, et al. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 2006; 77(1):81-95.
38. Yoshimura R, Shinkai K, Ueda N, et al. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients. Pharmacopsychiatry 2007; 40(1):9-13.
39. Cramer JA, Sernyak M. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Clin Ther 2004; 26(6): 905-914.
40. Wassef AA, Winkler DE, Roache AL, et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. Am J Psychiatry 2005; 162(2):330-339.
41. Abbott Laboratories. Depakote ER Divalproex Sodium Extended-Release Tablets, Formulary Information. Abbott Park, IL: Abbott Laboratories, 2000.
42. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002; 49(1):1-10.
43. Citrome L, Tremeau F, Wynn PS, et al. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol 2004; 24(3):255-259.
44. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2003; 3: CD004028.
45. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 1999; 56(10):950.
46. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001; 15(4):297-301.
47. Thomas R, Howe V, Foister K, et al. Adjunctive lamotrigine in treatment-resistant schizophrenia. Int J Neuropsychopharmacol 2006; 9(1):125-127.
48. Heck Ah, de Groot IW, van Harten PN. Addition of lamotrigine to clozapine in inpatients with chronic psychosis. J Clin Psychiatry 2005; 66(10):1333.
49. Chan YC, Miller KM, Shaheen N, et al. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophr Res 2005; 78(2-3):343-345.
50. Stuve W, Wessels A, Timmerman L. Remission of positive symptomatology of a schizophrenic psychosis after withdrawing lamotrigine: a case report. Eur Psychiatry 2004; 19(1):59-61.
51. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anticraving effect? J Psychopharmacol 2005; 19(3):301-305.
52. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54 (11):1241-1248.
53. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56(6): 441-446.
54. Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, et al. Does the addition of lamo-trigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy 2005; 2(3):399-406.
55. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007; 93(1-3):109-116.
56. Glaxo-Smith-Kline. A multicenter, double-blind, placebo-controlled, randomized, parallel group evaluation of the efficacy of a flexible dose of lamotrigine versus placebo as add-on therapy in schizophrenia. Study No. SCA30926. Available at: http://ctr.gsk.co.uk/Summary/lamotrigine/III_SCA30926.pdf. Accessed November 5, 2005.
57. Glaxo-Smith-Kline. A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of a flexible dose of lamotrigine compared to placebo as an adjunctive therapy to an atypical antipsychotic agent(s) in subjects with schizophrenia. Study No. SCA101464. Available at: http://ctr.gsk.co.uk/Summary/lamotrigine/III_SCA101464.pdf. Accessed May 27, 2006.
58. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of two placebo-controlled trials. J Clin Psychopharmacol 2007; 27(6):582-589.
59. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006; 4:CD005962.
60. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000; 45(2):198.
61. Levy E, Agbokou C, Ferreri F, et al. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007; 14(2):E234-E239.
62. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006; 82(1):115-117.
63. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28(4):169-175.
64. Drapalski AL, Rosse RB, Peebles RR, et al. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001; 24(5):290-294.
65. Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia. Am J Psychiatry 2002; 159(4):675.
66. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry 2003; 64(10):1267-1268.
67. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? J Clin Psychiatry 2004; 65(8):1145.
68. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res 2005; 52(5):392-394.
69. Tiihonen J, Halonen P, Wahlbeck K. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66(8):1012-1015.
70. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998; 43(3):305.
71. Megna JL, Devitt PJ, Sauro MD, et al. Gabapentin’s effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002; 36(1):12-16.
72. Jablonowski K, Margolese HC, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatry 2002; 47(10):975-976.
73. Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005; 20(3):179-181.
74. Hardoy MC, Carta MG, Carpiniello B, et al. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord 2003; 75(2):125-130.
75. Centorrino F, Albert MJ, Berry JM, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003; 5(5):370-374.
76. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004; 161(6):1130-1131.
77. Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J Clin Psychopharmacol 2003; 23(4): 419.
78. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol 1995; 11(2):55-59.
79. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in schizophrenia. Part II: Long-term pharmacotherapeutic strategies. Essent Psycho-pharmacol 2002; 5(1):17-30.
80. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series, treatment of schizophrenia. J Clin Psychiatry 1999; 60(suppl 11):43.
81. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizoph Res 1999, 35(suppl): S23-S33.
82. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull 2003; 37(suppl 2):74-88.
83. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psycho-pharmacol 2006; 26(5):467-473.
84. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005; 13(1):28-42.
85. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977; 55(4):299-308.